Table 5. Efficacy according to KRAS/NRAS/BRAF genotype.

	Patients		Progression-free survival (months) Range	Overall survival (months) Range
	No.	%
Overall evaluated population	67	100	13 3–113+	27 4–119+
KRAS exon 2 wild-type	23	37.5	14 3–93+	28 6+−97
KRAS exon 2 mutant	40	63.5	12 3–113+	21 4–119+
c.35 G > A KRAS mutant	16	25.3	8 3–113+	14 4–119+
KRAS exon 2-4 wild-type	21	33.3	13 3–93+	27 6+−97
KRAS exon 2-4 mutant	42	66.7	12 3–113+	27 4–119+
NRAS exon 2-4 wild-type	56	83.6	16 3–113+	28 4–119+
NRAS exon 2-4 mutant	11	16.4	12 6–93+	22 8–93+
BRAF wild-type	62	92.5	14 3–113+	28 4–119+
BRAF mutant	5	7.5	8 6–17	11 8–94+
KRAS/NRAS/BRAF wild-type	14	22.2	18 3–33	28 6+−97
KRAS/NRAS/BRAF mutant	49	77.8	12 3–113+	22 4–119+
Single mutant gene	40	63.5	14 3–113+	37 4–19+
≥2 mutant genes	9	14.3	11 6–17	22 8–94+

Abbreviations: No, number.